Targeting p160 SRCs in prostate cancer with bufalin (2)

ABSTRACT: The p160 Steroid Receptor Coactivators SRC-1, SRC-2, and SRC-3 are critical components of the AR transcriptional complex and are frequently upregulated in prostate cancer (PC). We showed that inhibition of the SRCs via a small molecule inhibitor significantly diminishes AR signaling output, expression of CRPC-associated transcripts and proliferation of CRPC cells both in vitro and in vivo.

ORGANISM(S): Homo sapiens

PROVIDER: GSE147213 | GEO | 2025/03/15

REPOSITORIES: GEO